‘I don’t have a checklist:’ Seagen CEO talks about his next stop, the Pfizer deal, and the ADC landscape
[ad_1]
David Epstein’s brief term as CEO of Seagen will likely come to an end soon with the company’s sale to Pfizer. Epstein is keeping an open mind about where he might go next after a rich career spanning enterprises of varying sizes.
“I will hopefully make new drugs somewhere else,” Epstein stated in a recent interview on the margins of the American Society of Clinical Oncology’s annual meeting. “I don’t know where that will be.”
Epstein has donned numerous hats in his stint in biopharma. He is well-known for establishing Novartis’ cancer division and overseeing the Swiss conglomerate’s bigger worldwide pharma business. He was the CEO of Flagship Pioneering for five years until joining Seagen in November.
[ad_2]
